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Abstract Simultaneously produced superoxide/nitric oxide ra-
dicals (Oc32 /NO
c) could form peroxynitrite (OONO3) which has
been found to cause atherogenic, i.e. oxidative modification of
LDL. Aromatic hydroxylation and nitration of the aspirin
metabolite salicylate by OONO3 has been reported. Therefore
we tested if salicylate may be able to protect LDL from
oxidation by Oc32 /NO
c by scavenging the OONO3 reactive
decomposition products. When LDL was exposed to simulta-
neously produced Oc32 /NO
c using the sydnonimine SIN-1,
salicylate exerted an inhibitory effect on LDL oxidation as
measured by TBARS and lipid hydroperoxide formation and
alteration in electrophoretic mobility of LDL. The cytotoxic
effect of SIN-1 pre-oxidised LDL to endothelial cells was also
diminished when salicylate was present during SIN-1 treatment
of LDL. Spectrophotometric analysis revealed that salicylate
was converted to dihydroxybenzoic acid (DHBA) derivatives in
the presence of SIN-1. 2,3- and 2,5-DHBA were even more
effective to protect LDL from oxidation by Oc32 /NO
c. Because
Oc32 /NO
c can occur in vivo, the results may indicate that
salicylate could act as an efficacious inhibitor of Oc32 /NO
c
initiated atherogenic LDL modification, thus further supporting
the rationale of aspirin medication regarding cardiovascular
diseases.
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1. Introduction
There is some experimental evidence that the oxidative
modi¢cation of LDL plays a pathophysiological role in the
onset of atherogenesis [1]. This observation has led to studies
dealing with the inhibition of LDL oxidation by drugs or
naturally occurring compounds [2^8]. Lipid peroxidation can
be initiated by e.g. copper ions, organic peroxyl radicals, hy-
pochlorite, tyrosyl radicals, tocopheryl radicals and Oc32 /NO
c
[9^13].
When Oc32 /NO
c are formed simultaneously, peroxynitrite
(OONO3) could be formed [14]. The highly reactive decom-
position products of OONO3 have been found to oxidise lip-
oproteins and membrane lipids [11,14^18]. In addition
OONO3 has been found to nitrate and hydroxylate amino
acids (i.e. tyrosine) [19^21] and nitro-tyrosine formation in
proteins has been suggested to be an indicator ^ although
not speci¢c ^ for in vivo formation of OONO3 [22]. The
pathophysiological consequences of tyrosine nitration have
been recently outlined by Ischiropoulos [23]. OONO3 induced
aromatic hydroxylation (and nitration) of salicylate has been
reported [24]. Taking these observations into account, one
could assume that salicylate may be able to protect LDL
from oxidative modi¢cation by scavenging the OONO3 reac-
tive decomposition products leading to lipid oxidation.
We report that salicylate inhibited the atherogenic modi¢-
cation of LDL initiated by Oc32 /NO
c. Spectroscopic analysis
revealed that in presence of SIN-1, a compound which gen-
erates simultaneously both radical species, salicylate is con-
verted to dihydroxybenzoic acid derivatives which were even
more e¡ective in inhibiting Oc32 /NO
c induced LDL oxidation.
2. Materials and methods
Salicylic acid (2-hydroxybenzoic acid), 2,3-dihydroxybenzoic acid
(2,3-DHBA), 2,5-dihydroxybenzoic acid (2,5-DHBA) and SIN-1 (3-
morpholinosydnonimine) were from Sigma Chemical Co., St. Louis,
MO, USA. All other chemicals used were of analytical grade.
2.1. LDL isolation
The isolation of LDL from human plasma followed procedures
reported previously [25]. The ¢nal preparation was ¢lter sterilised
and stored in 0.15 mol/l NaCl containing 0.1 mmol/l EDTA.
2.2. Lipoprotein oxidation
LDL (1 to 2 mg protein/ml) was incubated in 0.15 mol/l NaCl,
0.025 mol/l phosphate, pH 7.4 with or without SIN-1 for up to 18 h
at 37‡C [11,26].
2.3. Measurement of lipid oxidation
LDL oxidation products were measured as TBARS and total lipid
hydroperoxides. Brie£y, to 250 Wl sample 0.5 ml of TBARS reagent
(15% trichloroacetic acid; 0.375% thiobarbituric acid; 0.25 N hydro-
chloric acid) [27] was added and incubated at 100‡C for 45 min. After
cooling and centrifugation at 1000Ug for 10 min the absorbance was
determined at 535 nm. Malondialdehyde concentration was calculated
using an extinction coe⁄cient of 1.56U105 M31 cm31. Salicylate, 2,3-
and 2,5-DHBA did not interfere with TBARS formation. As 2,3- and
2,5-DHBA (but not salicylate) were found to interfere with the lipid
hydroperoxide (LPO) assay reported by El Sadaany [28], samples
(100 Wl) were applied to 0.9U2.0 cm Sephadex G-50 columns
(NICK Column, Pharmacia Biotech) equilibrated with 0.15 M NaCl
and eluted according to the manufacturer’s protocol. 0.4 ml of sample
was mixed with 1.0 ml LPO reagent and incubated for 60 min at 37‡C
(Wallin and Camejo [29]). Absorbance was read at 365 nm and LPO
concentration was calculated using an extinction coe⁄cient of
1.73U104 M31 cm31 [28].
2.4. Electrophoresis
20 Wg of treated or untreated LDL were analysed on cellulose
acetate sheets. Electrophoresis was run in veronal bu¡er pH 8.6 at
250 V for 60 min. Lipoproteins were stained with Ponceau Red S.
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Measurement of relative electrophoretic mobility (REM) was taken as
an indicator of LDL oxidation [1,9], setting the electrophoretic mobi-
lity of untreated LDL arbitrarily as 1.
2.5. Endothelial cells
Bovine arterial endothelial cells (BAEC) were prepared and cul-
tured as previously reported [30]. Cells were seeded in 6 well culture
plates. After cells had reached con£uency the cells were washed with
Hank’s balanced salt solution (HBSS) and further cultured for 18 h in
the absence or presence of the respective LDL preparation (0.4 mg/ml
HBSS) as indicated in the ¢gure legends.
2.6. Cytotoxicity
The release of lactate dehydrogenase activity (LDH) into the cell
culture medium was taken as an indicator of cytotoxicity. LDH ac-
tivity was measured by a commercial test kit (Boehringer Mannheim
Automated Analysis for BM/Hitachi 717, Germany).
2.7. Analysis of salicylate hydroxylation products
Hydroxylation products of salicylate were analysed spectrophoto-
metrically exactly as described in [31] using 2,3-DHBA as a standard.
Salicylate (2 mmol/l) was incubated in 0.15 mol/l NaCl, 0.025 mol/l
phosphate, pH 7.4 (¢nal volume 2.0 ml) in the presence or absence of
SIN-1 (up to 5 mmol/l) at 37‡C for 18 h and subsequently the hy-
droxylation products estimated.
3. Results and discussion
3.1. LDL oxidation
LDL was subjected to Oc32 /NO
c induced lipid oxidation us-
ing the sydnonimine SIN-1, which generates simultaneously
both radical species in solution at 37‡C [11]. LDL was incu-
bated for 15 h at 37‡C with SIN-1 (1 mmol/l) in the absence
or presence of salicylate and subsequently lipoprotein oxida-
tion was monitored by TBARS (MDA) and LPO formation.
Salicylate from 0.125 to 1 mmol/l exerted a concentration
dependent decrease in MDA concentration when present in
SIN-1/LDL incubations (see Fig. 1). 1 mmol/l salicylate sup-
pressed MDA concentration from 0.96 Wmol/l (= 100%) to
0.48 Wmol/l. Lipid hydroperoxides were also reduced to about
50% (see inset Fig. 1). It should be mentioned that plasma
levels up to 2 mmol/l of salicylate can be reached during
aspirin therapy [32]. In addition, electrophoretic analysis re-
vealed that the SIN-1 (1 mmol/l) induced increase in REM,
which is a further indicator of LDL oxidative modi¢cation,
was substantially decreased in the presence of 1 mmol/l salic-
ylate (see Fig. 2).
Oxidised LDL is cytotoxic to a variety of cells [33,34]. Fig.
3 shows the cytotoxic e¡ect of Oc32 /NO
c pretreated LDL on
cultured endothelial cells. SIN-1 oxidised LDL preparations
added to BAECs caused an about 50-fold increase in LDH
release into the culture medium. This was not due to cytotoxic
undecomposed SIN-1 in the culture medium, as it was shown
in a control experiment, that 18 h preincubated SIN-1
(1 mmol/l) did not cause any cytotoxicity (SIN-1: 2.5 þ 0.5
U/l vs. control : 4 þ 2 U/l). Salicylate when present during
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Fig. 1. E¡ect of salicylate, 2,3- and 2,5-DHBA on SIN-1 induced
LDL oxidation. LDL (1 mg/ml) was incubated in the presence or
absence of the respective compound (0.031 to 1 mmol/l) with SIN-1
(1 mmol/l) for 15 h at 37‡C. LDL oxidation was monitored by
TBARS formation as given in Section 2. 100% represents 0.96
Wmol/l MDA. Salicylate (R), 2,3-DHBA (a), 2,5-DHBA (b). Inset:
Lipid hydroperoxides (LPO) in SIN-1 (1 mmol/l) treated LDL in
absence (1) or presence of salicylate (2), 2,3-DHBA (3) or 2,5-
DHBA (4). All compounds 1 mmol/l.
Fig. 2. E¡ect of salicylate, 2,3- and 2,5-DHBA (1 mmol/l each) on
SIN-1 induced changes of LDL electrophoretic mobility. LDL
(2 mg/ml) was incubated in the presence or absence of SIN-1
(1 mmol/l) for 18 h at 37‡C. Lipoproteins were separated as given
in Section 2.
Fig. 3. E¡ect of salicylate on endothelial cell cytotoxicity of SIN-1
pretreated LDL. LDL was preincubated with SIN-1 (1 mmol/l) in
the absence or presence of salicylate for 18 h at 37‡C. Subsequently
endothelial cells were treated with the respective LDL preparations
(0.4 mg/ml) for 18 h and cytotoxicity was monitored by LDH
release as given in Section 2. 1: untreated cells ; 2: cells+LDL;
3: cells+LDL/salicylate (1 mmol/l); 4: cells+LDL/SIN-1; 5: cells+
LDL/SIN-1+1 mmol/l salicylate, 6: cells+LDL/SIN-1/0.5 mmol/l sa-
licylate; 7: cells+LDL/SIN-1/0.25 mmol/l salicylate; 8: cells+LDL/
SIN-1/0.125 mmol/l salicylate.
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the SIN-1/LDL oxidation reaction e¡ectively counteracted the
cytotoxic e¡ect.
Thus one may assume that salicylate may have scavenged
the radical species resulting from SIN-1 or the reactive peroxy-
nitrite decomposition products that is Oc32 /NO
c and OHc/
NOc2, respectively. However, it has to be explicitly stressed
that there is still a considerable debate regarding OHc forma-
tion from OONO3 [23,35]. Nevertheless, hydroxylation (and
nitration) of salicylate may occur during SIN-1/salicylate in-
cubation, thus protecting LDL from reactive radical species.
The hydroxylation derivatives generated from salicylate by
OHc attack had been identi¢ed as mainly 2,3-DHBA (49%)
and 2,5-DHBA (40%) and to a minor extent catechol (11%)
[30]. As can be seen in Fig. 4 when salicylate (2 mmol/l) was
incubated in presence of SIN-1 (up to 5 mmol/l) at 37‡C for
18 h, salicylate hydroxylation products were formed. At the
highest concentration tested, 2% of the salicylate was hy-
droxylated by SIN-1 treatment. However, it has to be men-
tioned that the spectrophotometric method used detects about
50^70% of reaction products as outlined in [31], but is very
suitable to indicate salicylate hydroxylation [31]. 2,3-DHBA
and 2,5-DHBA may have good radical scavenging (antioxi-
dant) properties due to their diphenolic nature. In SIN-1/LDL
incubation mixtures both compounds showed strong LDL
protective action compared to salicylate as measured by
MDA formation (Fig. 1). The alteration in REM of LDL
by SIN-1 was also counteracted by 2,3- and 2,5-DHBA (see
Fig. 2). The LPO concentrations in SIN-1 treated LDL were
decreased from 7.28 Wmol/l (SIN-1; 1 mmol/l) to 3.64 and
2.42 Wmol/l by 2,3-DHBA and 2,5-DHBA, respectively when
present at 1 mmol/l during LDL oxidation reaction (see inset
Fig. 1).
In summary, the present study suggests that salicylate is an
e⁄cacious antioxidant in the Oc32 /NO
c induced oxidation of
LDL. This was obviously due to the ability of salicylate to
scavenge the reactive decomposition products of peroxynitrite
and salicylate-hydroxylation (nitration) products are formed.
These products, i.e. 2,3- and 2,5-DHBA (the latter represents
the pharmacological salicylate metabolite) are still potent anti-
oxidants, thus supporting the salicylate e¡ect. Salicylate (as-
pirin) has been favoured as a preventive for cardiovascular
disease [36] due to its antithrombotic potential, but this med-
ication may also have a bene¢cial e¡ect regarding LDL oxi-
dation caused by Oc32 /NO
c and OONO3, respectively.
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Fig. 4. Hydroxylation of salicylate by SIN-1. Salicylate (2 mmol/l)
was incubated in the presence or absence of SIN-1 up to 5 mmol/l
at 37‡C for 18 h and the reaction products were estimated as de-
scribed in Section 2.
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